Released Presentations
PLENARY SESSIONS

FIRST PLENARY SESSION: CREATING SUSTAINABLE HEALTH SYSTEMS IN EUROPE

Creating Sustainable Health Systems In Europe
Carin A. Uyl-de Groot, Professor of Health Technology Assessment, Head of Health Economics & Director, Institute for Medical Technology Assessment/Institute of Health Care Policy and Management (iMTA/iBMG), Erasmus University Rotterdam, Rotterdam, The Netherlands
Delivering Affordable Cancer Care
Richard Sullivan, Director, Kings Health Partners Institute of Cancer Policy & Global Health, London, UK
Health Care Reform In Europe: moving towards integrated care and matching performance-based payment systems
Maureen P. M. H. Rutten-van Mölken, Professor of Economic Evaluations of Innovative Health Care for Chronic Diseases, Institute for Medical Technology Assessment/Institute of Health Care Policy and Management (iMTA/iBMG), Erasmus University Rotterdam, Rotterdam, Netherlands
Differential Pricing Across Europe Addressing Central-Eastern European Country Needs
Zoltán Kaló, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE) and Founder & CEO, Syreon Research Institute, Budapest, Hungary
High quality of care for all within a sustainable health care system
Lieven Annemans, Professor of Health Economics, Ghent University, Gent, Belgium

 

SECOND PLENARY SESSION: EARLIER ACCESS TO INNOVATION - IS IT WORTH IT?

Earlier Access To Innovation – Is It Worth It?
Adrian Towse, 2014-2015 ISPOR President and Director, Office of Health Economics, London, UK
Earlier Access To Innovation – Is It Worth It? The Regulatory Perspective
Hans-Georg Eichler, Senior Medical Officer, European Medicines Agency (EMA), London, UK
Earlier Access To Innovation – Is It Worth It? The Industry Perspective
Richard Bergström, Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium
Earlier Access To Innovation – Is It Worth It? HTA Agency Perspective - Germany
Alric Rüther, Head, Department of Health Care Quality, International Affairs, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
Earlier Access To Innovation – Is It Worth It? HTA Agency Perspective - UK
Carole Longson, Director, Centre for Health Technology Evaluation and Executive Director, National Institute for Health Care & Excellence (NICE), London, UK

 

THIRD PLENARY SESSION: HEALTH CARE EVIDENCE: CAN WE GET TO THE 'REAL WORLD'?

Health Care Evidence: Can We Get To The 'Real World'?
Finn Børlum Kristensen, Professor, Health Services Research & Health Technology Assessment, University of Southern Denmark and Director, EUnetHTA Secretariat, Danish Health and Medicines Authority, Copenhagen, Denmark
The Nordic Healthcare Registries – Real Improvement to Outcomes Research
Lars Pedersen, Professor, Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
Pills, People, and Preferences: Evaluating Real-Life Practice in Pragmatic Trials
Hilary Pinnock, Reader, Asthma UK Centre for Applied Research, Centre for Population Health Sciences, University of Edinburgh and General Practitioner, Whitstable Medical Practice, Whitstable, Kent, UK
Strategies to Reduce Bias and Increase Meaningfulness of Findings from Real World Data
Sebastian Schneeweiss, Professor of Medicine and Epidemiology, Harvard Medical School, Boston, MA, USA

 

ISSUE PANEL PRESENTATIONS

IP1 : HOW CAN HTA BENEFIT FROM INCREASED DATA TRANSPARENCY?

How Can HTA Benefit From Increased Data Transparency?
Meindert Boysen, Director, Technology Appraisal Programme, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester, UK
How Can HTA Benefit From Increased Data Transparency?
Jens Grueger, Vice President, Head of Global Health Economics & Pricing, Global Health Economics & Pricing, F. Hoffmann-La Roche, Basel, Switzerland
How Can HTA Benefit From Increased Data Transparency?
Beth S Woods, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK

 

IP2 : SUCCESS CRITERIA OF GENERIC AND BIOSIMILAR DRUG POLICIES: NOT AS EASY AS IT LOOKS

Success Criteria Of Generic And Biosimilar Drug Policies: Not As Easy As It Looks
Anke-Peggy Holtorf, Managing Director, Health Outcomes Strategies, Basel, Switzerland
Tomas Tesar, Member, Reimbursement Committee of the Slovak Ministry of Health, Union Health Insurance Fund, Bratislava, Slovak Republic
Nick Haggar, Head, Western Europe, Middle East and Africa and President, European Generic Medicines Association (EGA), Brussels, Belgium
Zoltán Kaló, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary

 

IP3 : HOW DESIRABLE, FEASIBLE, AND ACCEPTABLE IS THE INCLUSION OF REAL-WORLD EVIDENCE IN HTA DECISION MAKING ACROSS EUROPE?

Inclusion of Real-World Evidence (RWE) in Health Technology Assessment (HTA) : Feasibility and Technical Issues
Keith R Abrams, Professor of Medical Statistics & Head of Biostatistics Research Group, Department of Health Sciences, University of Leicester, Leicester, UK
The GetReal Project
Sarah Garner, Associate Director for Research and Development, National Institute for Health and Care Excellence (NICE), London, UK
Real World data and HTA decision making in Europe
Wim Goettsch, Project Leader, EUnetHTA JA2, Work Package 5 Rapid Assessments, Zorginstituut Nederland, Diemen, The Netherlands
Leadership in Real-World Evidence
Alexandre Joyeux, Director, Global Patient Access, Novartis Pharma AG, Basel, UK

 

IP4 : SHOULD WE ADJUST OVERALL SURVIVAL ESTIMATES FOR TREATMENT SWITCHING IN ONCOLOGY?

Should We Adjust Overall Survival Estimates for Treatment Switching in Oncology?
Stefan Holmstrom, Director, HEOR, Astellas Pharma Global Development, Leiden, The Netherlands
Nicholas R Latimer, Professor of Health Economics, ScHARR, Health Economics and Decision Science, University of Sheffield, Sheffield, UK
Yvonne-Beatrice Böhler, Professor for Pharmamanagement, Faculty of Applied Natural Sciences, Cologne University of Applied Sciences, Leverkusen, Germany
Anke van Engen, Senior Director, Quintiles Consulting, Hoofddorp, The Netherlands

 

IP5 : IT’S NOT SO LONELY ANYMORE: HOW ARE HEALTH SYSTEM PLAYERS ADAPTING VALUE DEMONSTRATION AND ACCESS PATHWAYS TO ADDRESS AN INCREASINGLY CROWDED ORPHAN AND NICHE PRODUCT AREA IN ORDER TO OPTIMIZE PUBLIC HEALTH?

Its Not so Lonely Anymore: How Are Health System Players Adapting Value Demonstration and Access Pathways to Address an Increasingly Crowded Orphan and Niche Project Area in Order to Optimize Public Health?
John J Doyle, Managing Director & Practice Leader, Managed Markets, US, Market Access, Quintiles, Hawthorne, NY, USA
Josie Godfrey, Associate Director, Highly Specialised Technologies, National Institute for Health and Care Excellence (NICE), London, UK
Donald Han, Vice President, Payer Insights & Access Regional Lead, Pfizer, Collegeville, PA, USA
Eric C Faulkner, Practice Leader, Global Market Access, Quintiles, Executive Director, Genomics, Biotech, Emerging Medical Technology Institute, National Association of Managed Care Physicians, and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA

 

IP6 : WHAT VALUE DO WE PLACE ON A CURE? VALUE DEMONSTRATION CHALLENGES ASSOCIATED WITH INNOVATOR AND REGENERATIVE THERAPIES IN EUROPE, NORTH AMERICA, AND ASIA

What Value Do We Place on a Cure? Value Demonstration Challenges Associated with Innovator and Regenerative Therapies in the EU, North America and Asia
Eric C Faulkner, Practice Leader, Global Market Access, Quintiles, Executive Director, Genomics, Biotech, Emerging Medical Technology Institute, National Association of Managed Care Physicians, and Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA
Adrian Towse, Director, Office of Health Economics, London, UK
Don Husereau, Adjunct Professor, Faculty of Medicine, University of Ottawa and Senior Scientist, University for Health Sciences, UMIT, Ottawa, ON, Canada
Joshua J. Carlson, Consultant, VeriTech Corporation, Mercer Island, WA, USA

 

IP7 : ARE WE MOVING TOWARDS COLLABORATIVE EUROPEAN RAPID RELATIVE EFFECTIVENESS ASSESSMENTS? INSIGHTS GLEANED FROM THE EUNETHTA JOINT ASSESSMENT OF CANAGLIFLOZIN

EUnetHTA REA of Canagliflozin - The Developer’s Perspective
Adrian D. Griffin, Vice President, HTA & Market Access Policy, Johnson & Johnson, Buckinghamshire, UK
Are We Moving Towards Collaborative European Rapid REA? - The Author's Perspective
Mirjana Huic, Assistant Director, Department for Development, Research and HTA, Agency for Quality and Accreditation in Health Care and Social Welfare, Zagreb, Croatia
Are We Moving Towards Collaborative European Rapid REA? A National HTA Agency perspective
François Meyer, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Paris, France
Are We Moving Towards Collaborative European Rapid Relative Effectiveness Assessments?
Diana Simone Warren, Assistant Project Manager, EUnetHTA WP5 Lead, National Health Care Institute (ZIN), Diemen, The Netherlands

 

IP8 : DOES THE DATA SPEAK FOR ITSELF? A LOOK AT ADEQUATE DATA GENERATION TO MEET THE DIFFERING REQUIREMENTS OF MULTIPLE HTA AND REIMBURSEMENT BODIES IN EUROPE

Does the Data Speak for Itself? Adequate Data Generation to Meet the Differing Requirements of Multiple HTA and Reimbursement Bodies in Europe
Timothy R Auton, Director, Astellas, Leiden, The Netherlands
Think Globally and Implement Locally
Omar Dabbous, Head of Quantitative Sciences, Payer Evidence Group, GlaxoSmithKline, King of Prussia, PA, USA
Does the Data Speak for Itself? Adequate Data Generation to Meet the Differing Requirements of Multiple HTA and Reimbursement Bodies in Europe - A Local AMNOG Perspective
Friedhelm Leverkus, Director, HTA&OR, Pfizer Deutschland GmbH, Berlin, Germany

 

IP9 : DOES BURDEN OF DISEASE FIT INTO OUR APPROACHES TO ASSESSMENT AND APPRAISAL?

Does burden of disease fit into our approaches to assessment and appraisal?
Measuring severity of illness
Elly Stolk, Assistant Professor, Erasmus University Rotterdam, Rotterdam, The Netherlands
Severity and drug reimbursement decisions
Morten Aaserud, Health Economist, NOMA, Oslo, Norway
Severity of disease: a relevant criterion for resource allocation?
Gert Jan van der Wilt, Professor of Health Technology Assessment, Department for Health Evidence, Radboud University Medical Centre, Nijmegen, The Netherlands

 

IP10 : HYPOTHETICAL VERSUS EXPERIENCE-BASED EQ-5D VALUATIONS: WHAT ARE THE IMPLICATIONS FOR HEALTH ECONOMIC EVALUATIONS?

Hypothetical versus experience-based EQ-5D valuations: What are the implications for health economic evaluations?
Ulf Persson, Chief Executive Officer, The Swedish Institute for Health Economics (IHE), Lund, Sweden
Gisela Kobelt, President, European Health Economics, Mulhouse, France
Johanna Svensson, Research Manager, The Swedish Institute for Health Economics (IHE), Lund, Sweden
Lars-Åke Levin, Professor, Department of Medical and Health Sciences, IMH, Linköping University, Linköping, Sweden

 

IP11 : DECISION MAKING IN HEALTH CARE BASED ON ECONOMIC EVALUATION: REALITY OR JUST WISHFUL THINKING? EXPERIENCES FROM FOUR EUROPEAN COUNTRIES

Decision-Making In Health Care Based On Economic Evaluations: Reality Or Just Wishful Thinking? Experiences From 4 European Countries
Andreas Uwe Gerber-Grote, Head, Department of Health Economics, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany
James P Raftery, Professor, NIHR Evaluation Trials and Studies Coordinating Centre (NETSCC), University of Southampton, Southampton, UK
Margreet Franken, Researcher, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
Emelie Heintz, Researcher, SBU, Stockholm, Sweden

 

IP12 : INTEGRATED CARE MODELS AS A POTENTIAL ROUTE FOR MARKET ACCESS OF INNOVATIVE MEDICAL DEVICES IN GERMANY? STAKEHOLDER PERSPECTIVES ON THE CONCEPT

Integrated Care Models as a Potential Route for Market Access of Innovative Medical Devices in Germany? Stakeholder Perspectives on the Concept
Stefan Walzer, General Manager, MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany
Integrated Care Models as a Potential Route for Market Access of Innovative Medical Devices in Germany? Perspectives on the concept: The industry
Daniel Droeschel, Health Economist, MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany
Integrated Care in Germany: A potential route to market access for medical devices?
Detlef Parow, Head of Health Care Management, DAK Gesundheit, Hamburg, Germany
Integrated Care in Germany: Potential route for medical devices
Mathias Flume, Head of Health Care Management, Kassenaerztliche Vereinigung Westfalen-Lippe, Dortmund, Germany

 

IP14 : REAL-WORLD COST-EFFECTIVENESS ANALYSIS: WHICH COMPARATOR HAS THE ULTIMATE X-FACTOR?

Real World Cost Effectiveness Analysis: Which Compartor has the X-Factor
Carin A Uyl-De Groot, Director, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands
Peter C. Huijgens, Director, The Comprehensive Cancer Centers The Netherlands (IKNL), Amsterdam, The Netherlands
Jolanda de Boer, Department Secretary, Scientific Advisory Committee, National Health Care Institute (ZIN), Diemen, The Netherlands
Elisabeth Maria van Rooijen, Junior Researcher, Institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, The Netherlands

 

IP15 : HOW SHOULD A SOCIETAL PERSPECTIVE IN ECONOMIC EVALUATION BE IMPLEMENTED?

How Should a Societal Perspective in Economic Evaluation be Implemented?
Ansgar Hebborn, Head, Global Market Access Policy, F. Hoffmann-La Roche AG, Basel, Switzerland
How should a societal perspective be implemented?
Werner Brouwer, Professor, Institute for Health Policy and Management (iBMG), Erasmus University Rotterdam, Rotterdam, The Netherlands
How should a societal perspective in economic evaluation be implemented?
Karl Claxton, Professor of Economics, Centre for Health Economics and Department of Economics, University of York, Heslington, York, UK
How Should a Societal Perspective in Economic Evaluation be Implemented?
Mark J. Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

 

IP16 : MULTICRITERIA FOR REAL LIFE DECISION MAKING? PERSPECTIVES AND EXPERIENCE FROM THE FIELD

Multicriteria for Real Life Decision Making: Perspectives and Experience from the Field
Mireille Goetghebeur, Global Scientist, LASER Analytica, Montreal, QC, Canada
Improving assessment process of health technologies: Towards a MCDA approach?
François Meyer, Advisor to the President, International Affairs, Haute Autorité de Santé (HAS), Paris, France
MCDA at NICE
Sarah Garner, Associate Director, Research and Development, National Institute for Health and Care Excellence (NICE), London, UK
Multicriteria for real life decision making? Perspectives and experience from the field
Michele Tringali, Deputy Officer, HTA Program, Direzione Generale Salute, Regione Lombardia, Milan, Italy

 

IP17 : CAN WE ALLEVIATE NEGATIVE CONSEQUENCES OF EXTERNAL PHARMACEUTICAL PRICE REFERENCING IN MIDDLE EAST COUNTRIES?

Can We Alleviate Negative Consequences Of External Pharmaceutical Price Referencing In Middle East Countries?
Mahmoud Elmahdawy, Director, Hospital Pharmacy Administration, Central Administration for Pharmaceutical Affairs, Egyptian Ministry of Health, Cairo, Egypt

 

IP18 : IS THERE ROOM FOR MULTI-CRITERIA DECISION MAKING IN CENTRAL & EASTERN EUROPEAN COUNTRIES WITH SEVERE FINANCIAL CONSTRAINTS?

Is there a room for MCDA in CEE Region with severe financial constraints?
Katarzyna Kolasa, Senior Research Fellow, Department of Pharmacoeconomics, Medical University of Warsaw, Warsaw, Poland
Is there are a room for multi criteria decision making in Central-Eastern European countries with severe financial constraints?
Zoltan Kalo, Professor of Health Economics, Department of Health Policy and Health Economics, Eötvös Loránd University (ELTE), Budapest, Hungary
Multicriteria decision making (MCDA) in health care - Against
Pavel Vorobiev, President, Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia

 

IP19 : EARLY ACCESS TO THERAPIES THROUGH ADAPTIVE LICENSING: HOW DO YOU MAKE IT WORK FOR ALL KEY STAKEHOLDERS?

“Adaptive licensing” issue panel
Francois Lucas, Principal, Pope Woodhead and Associates, St. Ives, UK
Wim Goettsch, Project Leader, EUnetHTA JA2, Work Package 5 Rapid Assessments, Zorginstituut Nederland, Diemen, The Netherlands
Bruno Flamion, Pharmacological and Medical Expert, Federal Agency for Medicines and Health Products, Brussels, Belgium
Sanda Rocak, Global Value Strategy Lead, Global Market Access, Shire, Eysins, Switzerland

 

IP20 : CAN MIXED METHODS RESEARCH BE THE SOLUTION TO THE CHALLENGES OF PATIENT-CENTERED OUTCOME RESEARCH IN THE CONTEXT OF RARE DISEASES?

Experiential Patient Data is the new Black
Francois Houyez, Treatment Information and Access Director & Health Policy Advisor, European Organisation for Rare Diseases (Eurordis), Paris, France
How can Mixed Methods Research help?
Benoit Arnould, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France
Rare Disease Issues Panel
Tara Symonds, Head of PRO Centre of Excellence, Global Market Access, Global Health and Value, Pfizer Ltd., Tadworth, UK

 

WORKSHOP PRESENTATIONS

W1 : DECISION FRAMEWORKS AND THE ECONOMIC EVALUATION OF VACCINES

Decision frameworks and the economic evaluation of vaccines: A framework for uncertainty
Elisabeth Fenwick, Director, Health Economics, ICON Clinical Research, Oxford, UK
Specificities Of Health Economics In Vaccines’ Evaluation
Maarten J Postma, Professor, Department of Pharmacy, University of Groningen, Groningen, The Netherlands
Decision Frameworks and the Economic Evaluation of Vaccines
Mark Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

 

W2 : HEALTHY DECISIONS: TOWARDS UNCERTAINTY TOLERANCE IN OUTCOMES RESEARCH

Healthy Decisions: Towards uncertainty tolerance in outcomes research
Manuela A. Joore, Researcher, Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre, Maastricht, The Netherlands
Jill Bindels, Postdoctoral Researcher, Clinical Epidemiology and Medical Technology Assessment, CAPHRI, Maastricht University Medical Centre; Maastricht University, Maastricht, The Netherlands
Thomas Wilkinson, Adviser, Health Economics, NICE International, National Institute for Health and Care Excellence (NICE), London, UK
Wim Goettsch, Project Leader, EUnetHTA JA2, Work Package 5 Rapid Assessments, Zorginstituut Nederland, Diemen, The Netherlands

 

W3 : GENERATING EVIDENCE FOR PHARMACOEPIDEMIOLOGY, HEALTH OUTCOMES, AND EPIDEMIOLOGY THROUGH DIRECT-TO-SUBJECT STUDY APPROACHES

Generating Evidence For Pharmacoepidemiology, Health Outcomes And Epidemiology Through Direct-To-Subject Study Approaches
Florian Eichmann, Senior Director, Real World Research & Value, Kantar Health, Munich, Germany
Susan Sinclair, Associate Professor, Epidemiologist, Clinical Research Program, UNCW College of Health and Human Services, Wilmington, NC, USA
Suzanne Reed, Director, Epidemiology, ZEG Berlin, Berlin, Germany
Marco DiBonaventura, Vice President, Health Outcomes, Health Outcomes Practice, Kantar Health, New York, NY, USA

 

W5 : VALUE-BASED ASSESSMENT FOR NICE: HOW TO DO THE CALCULATIONS

Value Based Assessment for NICE: How to Do the Calculations
Jeanette Kusel, Head of Health Technology Assessment and Health Economics, Costello Medical Consulting Ltd., Cambridge, UK
Meindert Boysen, Director, Technology Appraisal Programme, Centre for Health Technology Evaluation, National Institute for Health and Care Excellence (NICE), Manchester, UK
Koonal K. Shah, Senior Economist, Office of Health Economics, London, UK
Anthony J Hatswell, Principle Consulting Economist, BresMed, Sheffield, UK

 

W7 : FROM EVALUATION TO IMPLEMENTATION: HOW TO ENSURE EFFICIENT INVESTMENT IN IMPLEMENTATION OF COST-EFFECTIVE TECHNOLOGIES IN CLINICAL PRACTICE

Value of Implementation - Getting cost-effective technologies into practice
Rita Faria, Research Fellow, Centre for Health Economics, University of York, Heslington, York, UK
On the Value of Spending on Clinical Practice Guidelines and Implementation Strategies
Ties Hoomans, Assistant Professor, Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands
From Evaluation To Implementation: How To Ensure Efficient Investment In Implementation Of Cost-Effective Technologies In Clinical Practice?
Stephen Palmer, Professor, University of York, Heslington, York, UK
Value of Implementation: Getting cost-effective technologies into practice
Sophie Whyte, Research Fellow, HEDS, ScHARR, University of Sheffield, Sheffield, UK

 

W8 : PATIENT REGISTRIES AS HTA TOOLS IN ECONOMIC OUTCOMES RESEARCH: REQUIREMENTS, BARRIERS, AND THE WAY FORWARD

Patient Registries as HTA Tools In Economic Outcomes Research: Requirements, Barriers, And The Way Forward
Marianne Klemp, Director, The Norwegian Knowledge Centre for the Health Services (NOKC), Oslo, Norway
Patient registries and HTA: Learning from different European experiences
Wim Goettsch, Project Leader, EUnetHTA JA2, Work Package 5 Rapid Assessments, Zorginstituut Nederland, Diemen, The Netherlands
PARENT - Cross border PAtient REgistries iNiTiative JA
Persephone Doupi, Senior Researcher, PARENT JA WP6 Leader, Information Department, National Institute for Health and Welfare (THL), Helsinki, Finland
Serving patient registries
Ivan Pristas, Public health specialist, Head of Medical Informatics and Biostatistics Service, Croatian National Institute of Public Health, Zagreb, Croatia

 

W9 : RISK MODELING AND HETEROGENEITY OF TREATMENT EFFECT

Heterogeneity of Treatment Effect
David M Kent, Professor of Medicine, Predictive Analytics and Comparative Effectiveness Center, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA
Risk modelling: General modelling strategy issues
Ewout W Steyerberg, Professor of Medical Decision Making, Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands

 

W10 : MAKING MODELS MORE ACCESSIBLE TO DECISION MAKERS

Making Models More Accessible to Decision Makers
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Making models more accessible to decision makers
Michael Barry, National Clinical Lead, HSE Clinical Strategy and Programmes, HSE Medicines Management Programme, Dublin, Ireland
Making Models More Accessible to Decision Makers
Laurie Fazio, Vice President, Dymaxium, Inc., Toronto, ON, Canada
Making Models More Accessible to Decision-Makers
Amy O'Sullivan, Director, HEOR, Vertex, Boston, MA, USA

 

W11 : THE APPLICATION OF HEALTH ECONOMIC GUIDELINES TO STRATIFIED MEDICINE

The Application Of Health Economic Guidelines To Stratified Medicine
Mark J. C. Nuijten, Founder, Ars Accessus Medica, Jisp, The Netherlands
Stratified medicine: factors to consider in its assessment
W. Ken Redekop, Associate Professor, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

 

W12 : WHAT DO PEOPLE WANT TO KNOW AND NOT WANT TO KNOW? USING STATED-PREFERENCE METHODS TO EVALUATE NEW DIAGNOSTIC TECHNOLOGIES

The Perceived Value of Alzheimer’s Disease Diagnostic Information
F. Reed Johnson, Senior Research Scholar, Duke Clinical Research Institute, Duke University, Durham, NC, USA
Axel C. Mühlbacher, Professor of Health Economics and Health Care Management, Institute Health Economics and Health Care Management, IGM, Hochschule Neubrandenburg, Neubrandenburg, Germany
Examples
Deborah A. Marshall, Canada Research Chair, Health Services and Systems Research and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada

 

W13 : ECONOMIC EVALUATION FOR LOW AND MIDDLE INCOME COUNTRIES: INTRODUCING THE BILL AND MELINDA GATES FOUNDATION GUIDELINES

A principles-based approach to economic evaluation
Paul Revill, Research Fellow, Centre for Health Economics, University of York, York, UK
Economic Evaluation for Low and Middle Income Countries: Introducing the Bill and Melinda Gates Foundation Guidelines
Mark J. Sculpher, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Gates Reference Case: background, structure and content
Thomas Wilkinson, Adviser, Health Economics, NICE International, National Institute for Health and Care Excellence (NICE), London, UK

 

W14 : THE ETHICAL AND LEGAL ISSUES AROUND THE USE OF SOCIAL MEDIA TO GET TO THE “REAL WORLD”

The Ethical and Legal Issues around the use of Social Media to Get to the “Real World”
Andrew Cox, Senior Research Associate, Evidera, London, UK
H. Keri Yang, Director, Global Health Outcomes, Merck & Co., Inc., West Point, PA, USA
Ruth Suter, Senior Director, Market Access and Patient Services, BioMarin Pharmaceuticals, San Rafael, CA, USA

 

W15 : MIXED METHODS RESEARCH WITHIN CLINICAL TRIALS: OPERATIONAL CONSIDERATIONS

Mixed Methods Research within Clinical Trials: Operational Considerations
Alexia Marrel, Associate Director, Health Economics and Outcomes Research, Mapi, Lyon, France
Frederico Calado, Associate Director, Global Patient Assess, Novartis, East Hanover, NJ, USA
Jean-Bernard Gruenberger, Global HEOR Director, GPA (Global Patient Access), Novartis, Basel, Switzerland
Xavier Fournie, Executive Vice President, Global Medical Affairs, Global Medical Affairs RWE, Mapi, Lyon, France

 

W17 : DYNAMIC SIMULATION MODELING TO EVALUATE COMPLEX SYSTEM INTERVENTIONS FOR HEALTH CARE DELIVERY RESEARCH – WHAT METHODS FOR WHAT PROBLEMS?

Dynamic Simulation Modeling To Evaluate Complex System Interventions For Health Care Delivery Research – What Methods For What Problems?
Deborah A. Marshall, Canada Research Chair, Health Services and Systems Research and Associate Professor, Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Alberta Bone and Joint Health Institute, Calgary, AB, Canada
Maarten J. IJzerman, Professor & Chair, Department of Health Technology & Services Research, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands
William Padula, Postdoctoral Fellow, University of Chicago, Chicago, IL, USA
William H. Crown, Chief Scientific Officer, Optum Labs, Cambridge, MA, USA

 

W18 : DEVELOPMENT, VALIDATION, AND USE OF OBSERVER-REPORTED OUTCOMES IN CLINICAL TRIALS: CHALLENGES AND SOLUTIONS

Observer-Reported Outcomes in Clinical Trials: Challenges And Solutions
Donald L. Patrick, Professor, Seattle Quality of Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA
Rob Arbuckle, Director, Adelphi Values Ltd., Bollington, UK
Laurie Beth Burke, Founder, LORA Group, LLC, Royal Oak, MD, USA

 

W19 : USING MULTI-CRITERIA DECISION ANALYSIS TO EVALUATE THE POTENTIAL OF BIOSIMILARS TO LOWER COSTS IN ONCOLOGY

Using Multi-Criteria Decision Analysis to Evaluate the Potential of Biosimilars to Lower Costs in Oncology
Charles Bennett, CoEE Endowed Chair in Medication Safety and Efficacy & Frank P. and Josie M. Fletcher Professor of Pharmacy, University of South Carolina, Columbia, SC, USA
Dennis W Raisch, Professor & Chair, PEPPOR Graduate Program, University of New Mexico College of Pharmacy, Albuquerque, NM, USA
Maarten J. IJzerman, Professor of Clinical Epidemiology & Health Technology Assessment (HTA) and Head, Department of Health Technology & Services Research, MIRA Institute for Biomedical Technology & Technical Medicine, University of Twente, Enschede, The Netherlands
Martin van der Graaff, Secretary, Pharmacoeconomics Advisory Committee, National Health Care Institute (ZIN), Diemen, The Netherlands

 

W21 : PATIENT ENGAGEMENT IN OUTCOMES RESEARCH: CURRENT STATUS, QUESTIONS, BELIEFS, AND FUTURE PERSPECTIVES

Patient Engagement In Outcomes Research: Current Status, Questions, Beliefs, And Future Perspectives
Todd Berner, Executive Medical Director, Urology, Astellas Scientific and Medical Affairs, Inc., Northbrook, IL, USA
Asha Hareendran, Senior Research Scientist, Evidera, London, UK
Rachel Harrington, Senior Regulatory Submissions Manager, Astellas Pharma Global Development, Northbrook, IL, USA
Amie M. Scott, Research Project Manager, Memorial Sloan Kettering Cancer Center, New York, NY, USA

 

W22 : VALUE OF INFORMATION — WHAT IS ITS VALUE FROM A MANUFACTURER'S PERSPECTIVE?

Value Of Information: What is its Value from a Manufacturer’s Perspective?
Aline Gauthier, Director, Health Economics and Outcomes Research, Amaris, London, UK
Kyle Dunton, Research Analyst, Health Economics and Outcomes Research, Amaris, London, UK
Stuart Carroll, Associate Director & Head of Marketing Access, UK & Ireland, Biogen Idec, London, UK

 

W23 : THE FIRST STEP TO IMPROVE PATIENTS’ HEALTH CARE IS TO KNOW WHAT TO IMPROVE: DEMONSTRATING THE USE OF ‘GROUP CONCEPT MAPPING’ AS A NOVEL WAY TO DEVELOP A PATIENT-CENTERED DISEASE MODEL AND ENRICH CONTENT VALIDITY

Demonstrating the Use of ‘Group Concept Mapping’ (GCM) as a Novel Way to Develop a Patient-Centered Disease Model and Enrich Content Validity
Louise Humphrey, Director & Head, Clinical Outcomes Assessment, Abacus International, Manchester, UK
Joseph C Cappelleri, Senior Director, Pfizer Inc., Groton, CT, USA
Tara Symonds, Head of PRO Centre of Excellence, Global Market Access, Primary Care Business Unit, Pfizer, Kent, UK
Thomas G. Willgoss, Project Manager, Clinical Outcomes Assessment, Abacus International, Manchester, UK

 

W24 : A TALE OF TWO AUDIENCES: OPTIMISING YIELD FROM EARLY ADVICE CONSULTATION WITH HTA AND REGULATORY ORGANISATIONS

A Tale of Two Audiences: Optimising Yield from Early Advice Consultation with HTA and Regulatory Organisations
Cyrus A. Chowdhury, CEO & Managing Director, CBPartners, New York, NY, USA & London, UK
Rachel Beckerman, Principal, Value Demonstration, CBPartners, New York, NY, USA
Matthieu R. Cuche, Director HCE & Reimbursement, Covidien AG, Zürich, Switzerland
Marije van Weelden, Director, Market Access & Pricing Europe, Ferring, Saint-Prex, Switzerland

 

W25 : HOW CAN PATIENT ONLINE COMMUNITIES INFORM INDUSTRY ABOUT BARRIERS TO MEDICATION ACCEPTANCE AND UNMET NEEDS? LESSONS LEARNED FROM A FRENCH MULTI-DISEASES STUDY USING A PATIENT ONLINE COMMUNITY

How can patient online communities inform industry about barriers to medication acceptance and unmet needs?
Benoit Arnould, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France
H. Gilet, Senior Research Manager, HEOR & Strategic Market Access, Mapi, Lyon, France
Michael Chekroun, Chief Executive Officer, carenity.com, Paris, France

 

W26 : HOW AN EARLY NETWORK META-ANALYSIS (NMA) HELPS INFORM CLINICAL TRIAL DESIGN AND TECHNOLOGY APPRAISAL (TA) SUBMISSIONS?

How an Early Network Meta-analyses Can Inform Clinical Design and Help with Technology Appraisal Submissions
Floortje E van Nooten, Associate Director, HEOR, Astellas, Leiden, The Netherlands
Yingxin Xu, Research Scientist, Meta Research, Evidera, Lexington, MA, USA
Kyle Fahrbach, Senior Biostatistician, Meta Research, Evidera, Lexington, MA, USA
Grace Jennings, Technical Adviser, National Institute for Health and Care Excellence (NICE), Manchester, UK

 

W27 : CHANGING PERSPECTIVES, CHANGING VALUES: MOVING BEYOND COST-EFFECTIVENESS ANALYSIS

Changing Perspectives, Changing Values: Moving Beyond Cost-Effectiveness Analysis
Josephine A. Mauskopf, Vice President, Health Economics, RTI Health Solutions, Research Triangle Park, NC, USA
Baudouin Standaert, Head, Health Economics, GlaxoSmithKline Vaccines, Wavre, Belgium
Stephanie R. Earnshaw, Vice President, Health Economics US, RTI Health Solutions, Research Triangle Park, NC, USA
The fiscal consequences attributed to changes in morbidity and mortality: A government perspective analytic framework
Mark Connolly, Managing Director, Global Market Access Solutions, Switzerland and United States, and Guest Researcher, University of Groningen, Groningen, The Netherlands

 

W28 : PATIENT-REPORTED OUTCOMES IN A PRODUCT’S LIFECYCLE: THE IDEAL AND THE REALISTIC STRATEGIES

Patient-Reported Outcomes in a Product’s Lifecycle: The Ideal and the Realistic Strategies
Somali Misra Burgess, Cheif Executive Officer & Research Director, Strategic Outcomes Services, Mission Viejo, AZ, USA
Brooke Witherspoon, Associate Director, Endpoint Outcomes, Boston, MA, USA

 

W29 : SUPPORTING DECISION MAKING WITH MCDA: RECOMMENDATIONS FOR DEALING WITH UNCERTAINTY

Supporting Decision Making with MCDA: Recommendations for dealing with uncertainty
Kevin Marsh, Director, Modelling and Simulation and Senior Research Scientist, Health Economics, Evidera, London, UK
Maarten J. IJzerman, Professor of Health Technology & Services Research, Health Technology & Services Research, MIRA Institute for Biomedical Technology & Technical Medicine and University of Twente, Enschede, The Netherlands
Henk Broekhuizen, PhD Student, Health Technology & Services Research, University of Twente, Enschede, The Netherlands
Karin Groothuis-Oudshoorn, Assistant Professor, Health Technology & Services Research, University of Twente, Enschede, The Netherlands

 

W30 : AS REAL AS IT GETS: CHALLENGES IN SETTING UP PATIENT REGISTRIES FOR THE COLLECTION OF REAL-WORLD DATA ON BEHALF OF POLICY MAKING

As real as it gets: Challenges in setting up patient registries for the collection of real-world data on behalf of policy making
Naomi van der Linden, Researcher, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
Margreet Franken, Researcher, Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands
Hans Westgeest, Medical Oncologist, Department of Medical Oncology, VU University Medical Center, Amsterdam, The Netherlands
Saskia de Groot, Researcher, institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands

 

W31 : CAN WE MAKE INDIRECT COMPARISONS AND NETWORK META-ANALYSIS USEFUL FOR CLINICIANS AND PATIENTS OR IS IT JUST FOR HEALTH TECHNOLOGY ASSESSMENTS?

Can we make network meta-analysis useful for clinicians and patients or is it just for HTAs?
Edward J Mills, Associate Professor, Stanford University, Stanford, CA, USA
How to make network meta-analysis more attractive to clinicians
Heiner C. Bucher, Professor, Internal Medicine, Basel Institute for Clinical Epidemiology & Biostatistics, Basel, Switzerland
Can we make network meta-analysis useful for clinicians and patients or is it just for HTAs?
Carl Baxter, EBM & OR Manager, MSD Ltd., Hoddesdon, UK

 

W32 : EVALUATION OF RISK-SHARING AGREEMENTS – A REAL-OPTION APPROACH

Evaluation of risk-sharing agreements: A real-option approach
Augustin Terlinden, Health Economist, Health Economics, Navigha, Tervuren, Belgium
Olivier Ethgen, Adjunct Professor Health Economics, University of Liege, Liege, Belgium

 

W33 : INTEGRATING THE PATIENT PERSPECTIVE IN THE ASSESSMENT OF BENEFITS AND RISKS OF MEDICINES

Integrating the patient perspective in the assessment of benefits and risks of medicines
Donald L. Patrick, Professor, Seattle Quality of Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA
Benoit Arnould, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France
Carla Dias Barbosa, Senior Research Manager, HEOR & Strategic Market Access, Mapi, Lyon, France
Kimberley Hockley, Research Postgraduate and Team Leader for Patients and Public Involvement Working Group of the IMI-PROTECT Work Package Five, School of Public Health, Imperial College London, London, UK

 

ISPOR FORUMS

F1 : AN INTRODUCTION TO MULTI-CRITERIA DECISION ANALYSIS IN HEALTH CARE DECISION MAKING - EMERGING GOOD PRACTICES

Multi-criteria decision analysis for healthcare decision making
Maarten J IJzerman, Professor & Chair, Department of Health Technology & Services Research, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Enschede, The Netherlands
Nancy Devlin, Research Director, Office of Health Economics, London, UK
Praveen Thokala, Research Fellow, School of Health and Related Research, University of Sheffield, Sheffield, UK
Kevin Marsh, Director, Modelling and Simulation and Senior Research Scientist, Health Economics, Evidera, London, UK

 

F3 : IMPROVING PATIENT CARE IN EUROPE BY HARMONIZING DIAGNOSTIC HTA: FINDINGS FROM THE HTA DIAGNOSTIC WORKING GROUP

Improving Patient Care in Europe by Harmonizing Diagnostic HTA: Findings From The HTA Diagnostic Working Group
Susan Garfield, Senior Vice President, Market Access, Health, GfK Bridgehead, Wayland, MA, USA
Eric Faulkner, Practice Leader and Director, Global Market Access, Quintiles Global Consulting and Assistant Professor, University of North Carolina, Durham, NC, USA
Anne Postulka, Director, Medical and Economic Value, Cepheid Europe, Maurens-Scopont, France
Karsten Berndt, Chair of EDMA HTA Task Force and Senior Project Manager Health Technology Assessment, Roche Diagnostics GmbH, Mannheim, Germany

 

F4 : RARE DISEASE: CHALLENGES IN ASSESSMENT AND APPRAISAL OF DIAGNOSTICS & TREATMENTS

Rare Disease Challenges in Assessment and Appraisal of Diagnostics & Treatments Working Group
Mondher Toumi, Professor & Chair of Decision Sciences, Department of Public Health and Market Access, University Claude Bernard Lyon I, Lyon, France
Ken Redekop, Associate Professor, Erasmus University Rotterdam, Rotterdam, The Netherlands
Chris L. Pashos, Vice President, Global Outcomes and Epidemiology Research, Takeda Pharmaceuticals International, Inc., Cambridge, MA, USA
Ruediger Gatermann, Director, Health Policy & External Affairs Europe, CSL Behring, Marburg, Germany

 

F5 : CAPACITY BUILDING IN PHARMACOECONOMICS AND HTA IN CENTRAL & EASTERN EUROPEAN (CEE): OPPORTUNITIES IN EDUCATION AND TRAINING

Croatia - Opportunities to Grow
Josip Culig, President, ISPOR Croatia Chapter and Professor, Pharmacology & Clinical Pharmacology & Head, Pharmacoepidemiology Department, Public Health Institute Zagreb, Zagreb, Croatia
Why to invest in capacity building in PE and HTA in CEE?
Rok Hren, President, ISPOR Slovenia Chapter and Assistant Professor, University of Ljubljana, Ljubljana, Slovenia
Capacity Building In Pharmacoeconomics and HTA in CEE: Opportunities In Education And Training
Mirela Sima, Health Economics Specialist, Johnson & Johnson, Bucharest, Romania
Capacity Building In Pharmacoeconomics And HTA In Central & Eastern European (CEE): Opportunities In Education And Training
Vladimir Zah, Health Economics Consultant & Founder, Zrx Outcomes Research Inc., Belgrade, Serbia and Montenegro
Capacity Building In Pharmacoeconomics And HTA In Central & Eastern European (CEE): Opportunities In Education And Training
Olha Zaliska, President, ISPOR Ukraine Chapter and Professor, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

 

F6 : STANDARD TREATMENT GUIDELINES (STG'S) AND THE EFFECT OF A LACK OF IMPLEMENTATION

Standard Treatment Guidelines (STG's) And The Effect Of A Lack Of Implementation
Mahmoud Elmahdawy, President, ISPOR Egypt Chapter, Head of Hospital Pharmacy Administration, Ministry of Health, and Lecturer, Clinical and Hospital Pharmacy, Misr International University, Cairo, Egypt
Barbara Castelnuovo, Director, Longitudinal Cohorts and Post-Doctoral Researcher Infectious Diseases Institute, Infectious Diseases Institute, Makerere University College of Health Sciences, Kampala, Uganda
Shelley McGee, Health Economist PRICELESS SA, Director, ISPOR South Africa Chapter and MRC/ WITS Rural Health and Health Transitions Unit, Wits University School of Public Health, Johannesburg, South Africa
Ola G. Al Ahdab Albannay, President, ISPOR United Arab Emirates Chapter and Pharmaceutical Advisor & Project Manager, Registration and Drug Control Department, Ministry of Health, Abu Dhabi, United Arab Emirates
Peter Agyei-Baffour, President, ISPOR Ghana Chapter and Lecturer & Researcher, Department of Community Health, School of Medical Sciences, Kwame Nkrumah University of Sciences and Technology (KNUST), Kumasi, Ghana
Anthony Waka Udezi, Assistant Dean of Pharmacy and Senior Lecturer, Department of Clinical Pharmacy, University of Benin, Benin City, Nigeria

 

F8 : HEALTH STATE UTILITY VALUES: MEASURING, MODELLING, AND MAPPING

Health State Utility Values: Measuring, Modelling, and Mapping
Sorrel Wolowacz, Head, European Health Economics, RTI Health Solutions, Manchester, UK
Andrew Briggs, Professor of Health Economics, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
Allan J Wailoo, Professor of Health Economics, ScHARR, University of Sheffield and Director, NICE Decision Support Unit, Sheffield, UK
Andrea Manca, Professor, Centre for Health Economics, University of York, Heslingon, York, UK

 

F9 : VALUE IN HEALTH REGIONAL ISSUES: EXAMINING PRACTICAL ASPECTS OF MANUSCRIPTS SUBMISSIONS

Scientometry evaluation of Value in Health Regional Issues
Imre Boncz, Co-Editor, Value in Health Regional Issues (CEEWAA) and Professor, Faculty of Health Sciences, University of Pécs, Pécs, Hungary
Examining Practical Aspects of Manuscripts Submissions: Plagiarism (Similarity Index)
Mohamed Izham b. Mohamed Ibrahim, Co-Editor, Value in Health Regional Issues (CEEWAA) and Professor of Social & Administrative Pharmacy, College of Pharmacy, Qatar University, Doha, Qatar
Value in Health Regional Issues (ViHRI): Writing Quality Manuscripts for Success
Bong-Min Yang, Co-Editor-in-Chief, Value in Health Regional Issues (Asia) and Professor of Economics, School of Public Health and Executive Director, Institute of Health and Environment, Seoul National University, Seoul, South Korea

 

F10 : THE BENEFITS OF INNOVATIVE MEDICINES IN CENTRAL & EASTERN EUROPEAN (CEE) COUNTRIES

The Benefits Of Innovative Medicines In Central & Eastern European (CEE) Countries
Dominik Tomek, Senior Researcher, Faculty of Medicine, Slovak Medical University, Bratislava, Slovak Republic
Benefits of investment in innovative drugs in CEE countries – examples from Republic of Macedonia
Zoran Sterjev, Vice-Dean, Faculty of Pharmacy, UKIM-Skopje, Skopje, Macedonia
The Benefits of Innovative Medicines in Russia
Liubov Krasnova, Executive Director, The Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia

 

F11 : THE POLICY CHALLENGES OF RARE DISEASES IN THE CENTRAL & EASTERN EUROPEAN (CEE) REGION

The Policy Challenges of Rare Diseases in the Russian Federation
Maria Avksentyeva, Deputy Director, HTA Centre at RANEPA (Russian Academy of National Economy and Public Administration), Moscow, Russia
The Policy Challenges of Rare Diseases in The CEE Region: Bosnia And Herzegovina Perspective
Tarik Catic, Health Economics Consultant, ISPOR Bosnia and Herzegovina Chapter, Sarajevo, Bosnia
The Policy Challenges Of Rare Diseases In The Central & Eastern European (CEE) Region: Orphan Drugs In The Czech Republic
Jan Hambalek, Head of Pharmacoeconomic Department, State Institute of Drug Control, Prague, Czech Republic
The Policy Challenges Of Rare Diseases In The Central & Eastern European (CEE) Region
Malwina Holownia, Director of Economics, The Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
The Policy Challenges Of Rare Diseases In The CEE Region - Poland
Karina Jahnz-Rozyk, Professor & Head, Department of Immunology & Allergology, Military Institute of Medicine, Warsaw, Poland

 

F12 : NEW DEVELOPMENTS IN HEALTH POLICY IN ITALY

Outcomes of care in Italy: moving towards a more reliable way to assess interventions
Paolo Angelo Cortesi, Research fellow, Research Centre on Public Health (CESP) - University of Milano-Bicocca, Monza, Italy
Patients and HTA, EUPATI, and ISPOR - Collaboration Matters
Filippo Buccella, President, Parent Project – Onlus, Chairman, EUPATI National Liaison Team Italy, Rome, Italy

 

EDUCATIONAL SYMPOSIA

END OF LIFE OR END OF THE ROAD: ARE RISING CANCER COSTS SUSTAINABLE?

End of life or end of the road? Are rising cancer costs sustainable?
Michael Drummond, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK
Monique Martin, Vice President & General Manager HEOR Europe, Optum, Uxbridge, UK
Alistair Mcguire, Professor of Health Economics, London School of Economics, London, UK
Nahila Justo, Associate Director, Optum, Stockholm, Sweden

 

LONG-TERM SURVIVAL IN CANCER PATIENTS – DEFINING NOVEL VALUE METRICS AND METHODOLOGIES IN AN ERA OF IMMUNO-ONCOLOGY MEDICINES

Long-Term Survival in Cancer Patients –Defining Novel Value Metrics and Methodologies in an Era of Immuno-Oncology Medicines
Bengt Jonsson, Professor Emeritus of Health Economics, Stockholm School of Economics, Stockholm, Sweden
Isabelle Durand-Zaleski, Director, URC Eco, Ile de France, Paris, France
Cilia Linssen, Board member, Lung Cancer Information Centre and Lung Cancer Europe, Haarlem, The Netherlands
David Chao, Consultant in Medical Oncology, Royal Free Hospital, London, UK

 

PODIUM AND POSTER PRESENTATIONS


For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 17th Annual European Congress, see: the ISPOR Scientific Presentations Database an electronic database of nearly 39,500 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Scientific Presentations Database
  • Under Meeting select ISPOR 17th Annual European Congress – Amsterdam, The Netherlands
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.
OPEN MEETINGS
EDUCATIONAL FORUM
STUDENT SHOWCASE
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.